Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced that the US FDA has granted Fast Track Designation to its allogeneic CAR T-cell therapy, azer-cel, for the treatment of relapsed or refractory diffuse large B-cell lymphoma. …
Imugene's azer-cel granted FDA Fast Track Designation in blood cancer
March 19, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 26 September
September 26, 2025 - - Podcast -
Waiting for any impact. Why the Albanese Government will hold fire on 'MFN'
September 26, 2025 - - Latest News -
Boehringer Ingelheim pushes for patient voices to lead policy reform
September 26, 2025 - - Latest News -
TGA consulting on the ongoing need for paper product information inserts
September 25, 2025 - - Latest News -
Gene therapy shows early promise in slowing Huntington’s Disease
September 25, 2025 - - Australian Biotech -
Federal minister to address AusBiotech International Conference as sector marks critical juncture
September 25, 2025 - - Australian Biotech -
Recce Pharmaceuticals begins patient dosing in pivotal diabetic foot infection trial
September 25, 2025 - - Australian Biotech